


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

**VOLUNTARY ANNOUNCEMENT
IND APPROVAL FOR LM-350 “CDH17 ADC” FROM THE US FDA**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that LM-350 “CDH17 ADC”, an innovative drug independently developed by LaNova Medicines Limited (“**LaNova Medicines**”, a wholly-owned subsidiary of the Group) has been granted the Investigational New Drug (IND) approval from the United States Food and Drug Administration (“**FDA**”).

LM-350 is an antibody-drug conjugate (ADC) targeting CDH17, developed based on LM-ADC™ (the next-generation ADC platform of LaNova Medicines) and can be combined with CDH17 with high selectivity, demonstrating strong internalization capability. LM-350 adopts a wild-type IgG1 configuration and exhibits antibody-dependent cell-mediated cytotoxicity (ADCC) killing activity. Preclinical studies have shown that LM-350 exhibits significant anti-tumor activity across multiple xenograft models, with notably strong efficacy in colorectal cancer cells resistant to MMAE or Irinotecan.

CDH17 plays a critical role in the invasion and metastasis of various tumors and is highly expressed in approximately 99% of colon cancers, 86% of gastric adenocarcinomas, 79% of esophageal adenocarcinomas, and 50% of pancreatic ductal adenocarcinomas^[1,2]. Gastrointestinal tumors (including colorectal, gastric, pancreatic, esophageal cancers, etc.) ranked one of the top among all types of cancers in terms of incidence and mortality worldwide, with over 4 million new patients reported globally in 2022, indicating significant unmet clinical needs^[3].

In addition to LM-350, the Group has five ADC products at clinical stages, including: TQB2102 (HER2 bispecific ADC) in Phase III, LM-302 (Claudin 18.2 ADC) in Phase III, LM-305 (GPRC5D ADC) in Phase I/II, TQB2101 (ROR1 ADC) in Phase I, TQB6411 (EGFR/c-Met ADC) in Phase I, as well as nearly ten other ADC products under preclinical development, which are expected to enter clinical trials within the next one to two years.

Sources:

- [1] Jiang Yifan, Zhang Yueying. Relationship between CDH17 and Tumor Progression [J]. World Journal of Cancer Research, 2021, 11: 131.
- [2] Panarelli NC, Yantiss RK, Yeh MM, Liu Y, Chen YT. Am J Clin Pathol. 2012 Aug;138(2):211-22.
- [3] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: a cancer journal for clinicians, 2024, 74(3): 229-263.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 24 July 2025

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.

* *For identification purpose only*